Clinical Trials Directory

Trials / Unknown

UnknownNCT04425798

Connectivity Alterations After Levetiracetam Application

Connectivity Alterations of Brain Network in LGG Patients After Levetiracetam Application at Short Term

Status
Unknown
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Beijing Neurosurgical Institute · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study aimed to analyze the connectivity alterations in brain networks of LGG patients with epilepsy who take levetiracetam at short-term preoperatively.

Detailed description

Glioma-related epilepsy (GRE) is a very common symptom in patients with diffuse gliomas. Approximately 60% of patients with low-grade gliomas (LGGs) and 40-64% of patients with high-grade gliomas presented with GRE at the onset. Although beneficial for the control of GRE, the overall therapeutic effect was unsatisfied and over 20% of patients still suffered from seizures. GRE was found to be associated with brain network and functional connectivity. And it has been reported that temporal lobe seizures could induce functional connectivity and decreased network efficiency of brain networks. However, the alterations in functional networks induced by GRE were still unclear. And LGG patients with GRE usually take levetiracetam (LEV) preoperatively, which could effectively reduce abnormal spike activity and further cause connectivity alterations. This makes it more complex to reveal the connectivity alterations of brain networks in LGG patients with GRE. This study aimed to collect the resting-state functional MRIs of 30 LGG patients who presented with GRE at the onset. Through further applied graph theory analysis, investigators tend to reveal the connectivity alterations of brain networks caused by levetiracetam. The findings of this study will provide a theoretical basis for further study of connectivity alterations of brain networks in patients with GRE.

Conditions

Timeline

Start date
2022-05-25
Primary completion
2022-05-31
Completion
2022-09-30
First posted
2020-06-11
Last updated
2020-06-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04425798. Inclusion in this directory is not an endorsement.